In addition, ruxolitinib led to an increase in the plasma levels of nitric oxide in 46% of the patients, and most of the patients had reductions in the levels of serum biomarkers of pulmonary hypertension, including the N-terminal prohormone of brain natriuretic peptide (73%), von Willebrand antigen (86%), ristocetin cofactor activity (73%), and uric acid (60%) [21,112]. Here, NPPB is linked to pulmonary hypertension.